HTG Molecular Diagnostics Inc, Tucson, Ariz, has released the HTG EdgeSeq diffuse large B-cell lymphoma (DLBCL) cell-of-origin assay. The most common form of non-Hodgkin’s lymphoma in adults, DLBCL is characterized by two major subtypes, activated B-cell-like (ABC) and germinal center B-cell-like (GCB).
The company’s assay classifies DLBCL as ABC or GCB, as validated on more than 250 cases previously subtyped through microarray-based gene expression profiling. Automated on the HTG EdgeSeq system, the assay couples HTG’s proprietary nuclease protection chemistry with next-generation sequencing (NGS).
Chris Roberts, HTG Molecular Diagnostics.
“In many cancers, like DLBCL, it is common for the core needle biopsy to be the only sample available for assessing the nature of the tumor,” says Chris Roberts, senior vice president of marketing and medical innovation at HTG. “We believe that the HTG EdgeSeq DLBCL cell-of-origin assay will be transformational because it enables the subtyping of DLBCL from these minimally invasive samples.”
In addition, the company also announced the availability of the HTG EdgeSeq lymphoma panel, which measures the expression of 93 genes frequently assessed in lymphomas, including 22 common markers of non-Hodgkin’s lymphoma.
TJ Johnson, HTG Molecular Diagnostics.
“We are proud to add these two new products to our growing portfolio of NGS-based molecular profiling assays, and we are pleased to enable our customers to perform NGS-based molecular profiling from core needle biopsies,” says TJ Johnson, chief executive at HTG. ”There is a trend toward a demand for more data from less tissue; we believe that this tissue availability issue will only grow as new biomarker-directed therapies are made available, and our solution will meet that demand.”
The DLBCL cell of origin assay is for research use only.
For more information, visit HTG Molecular Diagnostics.
